Drug Associated Toxic Nephropathy Identified in the United States Food and Drug Administration Adverse Event Reporting System Database

被引:0
|
作者
Balaha, Mohamed F. [1 ]
Ahmed, Nehad J. [1 ]
Khafagy, El Sayed A. [2 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Alkharj, Saudi Arabia
[2] Prince Sattam Bin Abdulaziz Univ, Dept Pharmaceut, Coll Pharm, Alkharj, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2022年 / 41卷 / 11期
关键词
adverse event; nephrotoxic drug; nephrotoxicity; reporting; ACUTE-RENAL-FAILURE; NEPHROTOXICITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acute kidney injury has a complex pathophysiology, but the main causes are sepsis, ischemia, and nephrotoxicity. Drugs cause about 20% of nephrotoxicity. The aim of this study was to describe reports of drug-associated toxic nephropathy. The FDA Adverse Event Reporting System was used to conduct a retrospective, descriptive analysis of all reported drug-associated nephrotoxicity. A total of 7924 reports of drug-associated toxic nephropathy were submitted to the FDA Adverse Event Reporting System. The most reported medications that were associated with toxic nephropathy were tacrolimus (11.21%), cyclosporine (11.13%), vancomycin (9.58%), cisplatin (6.51%), methotrexate (5.04%), mycophenolate mofetil (4.85%), cyclophosphamide (4.76%), prednisone (3.92%), etoposide (3.79%), and tenofovir disoproxil fumarate (3.15%). Immunosuppressive drugs, antibacterial agents, antineoplastic therapies, and antiviral drugs are among the most regularly used medications that have been recognized as potentially nephrotoxic. Early detection can be achieved through careful observation and monitoring of renal function, while fast discontinuation of toxic medical treatment is necessary to prevent additional damage and, in many cases, entirely reverse renal injury.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database
    Wu, Shi-Nan
    Chen, Xiao-Dong
    Yan, Dan
    Wang, Yu-Qian
    Wang, Shao-Pan
    Guan, Wen-Ying
    Huang, Caihong
    Hu, Jiaoyue
    Liu, Zuguo
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2025, 53 (02): : 140 - 160
  • [22] Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
    Wu, Ziyang
    Zhou, Pengxiang
    He, Na
    Zhai, Suodi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [23] Evaluating the process of standardizing investigational drug substance names reported to the United States Food and Drug Administration adverse event reporting system
    Fung, Maggie
    Brajovic, Sonja
    Patel, Nitin
    Chang, Sherry
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 189 - 190
  • [24] A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
    Rong, Li
    Xie, Mengyuan
    Jiang, Manxue
    Qiu, Hongyu
    Kong, Lingti
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (08) : 1816 - 1826
  • [25] Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database
    Xu, Ye
    Yan, Cilin
    Zhao, Ying
    Li, Dandan
    Guo, Mingxing
    Cui, Xiangli
    CANCER MEDICINE, 2023, 12 (08): : 9167 - 9174
  • [26] Pancreatitis Associated With Teduglutide: A Disproportionality Analysis via the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Gu, Joyce H.
    Sheingold, Zachary
    Samarneh, Mark
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [27] A Summary of the Rare Reports of Osteonecrosis of the Jaw Associated With Tumor Necrosis-a Inhibitors in the United States Food and Drug Administration's Adverse Event Reporting System Database
    Wichelmann, Thomas Adam
    Ahdi, Hardeep S.
    Pandravada, Sasirekha
    Ehrenpreis, Eli D.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2023, 81 (10) : 1311 - 1318
  • [28] Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database
    Wei, Lianhui
    Tian, Ye
    Chen, Xiao
    Guo, Xiaojing
    Chen, Chenxin
    Zheng, Yi
    Xu, Jinfang
    Ye, Xiaofei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (03) : 622 - 629
  • [29] Novel Adverse Event of Atezolizumab: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Ahmed, Abdul Mannan Faruk
    Maheswari, Eswaran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 306 - 306
  • [30] Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database
    Lianhui Wei
    Ye Tian
    Xiao Chen
    Xiaojing Guo
    Chenxin Chen
    Yi Zheng
    Jinfang Xu
    Xiaofei Ye
    International Journal of Clinical Pharmacy, 2023, 45 : 622 - 629